References
- Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012; 39:323 - 39; http://dx.doi.org/10.1053/j.seminoncol.2012.02.006; PMID: 22595055
- Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
- Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011; 60:1227 - 42; http://dx.doi.org/10.1007/s00262-011-1020-8; PMID: 21544650
- Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One 2013; 8:e70417; http://dx.doi.org/10.1371/journal.pone.0070417; PMID: 23894654
- Ardiani A, Farsaci B, Rogers CJ, Protter AA, Guo Z, King TH, Apelian D, Hodge JW. Combination therapy with a second-generation androgen receptor antagonist and a aetastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 2013; Forthcoming http://dx.doi.org/10.1158/1078-0432.CCR-13-1026; PMID: 24048332
- Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013; 133:624 - 36; http://dx.doi.org/10.1002/ijc.28070; PMID: 23364915
- Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259 - 71; http://dx.doi.org/10.1084/jem.20052494; PMID: 16636135
- Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?. Immunol Invest 2006; 35:485 - 503; http://dx.doi.org/10.1080/08820130600808246; PMID: 16916763
- C.R. Heery NKI, Mohebtash M, Madan R.A, Arlen P.M, Bilusic M, Kim J.W, Singh N.K, Hodge S, McMahon S, Steinberg S.M, Hodge J.W, Schlom J, Gulley J. A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM. Cancer research 2012; 72(24 Suppl):Abstract nr P5-16 - 06
- Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, et al. Interim analysis of a phase II randomized clinical trial of samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. In: American Society of Clinical Oncology: 2012; Chicago, Illinois: ASCO; 2012: 2526.